Who are Daily infusion of dornase alfa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dornase alfa (Pulmozyme), rhDNAse, Pulmozyme®, Dornase Alfa Inhalant Solution [Pulmozyme], Dornase Alfa Inhalation Solution, Fabrazyme (agalsidase beta).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daily-infusion-of-dornase-alfa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Daily infusion of dornase alfa — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daily infusion of dornase alfa (Daily infusion of dornase alfa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant enzyme. Area: Pulmonary/Respiratory.

phase 2 Recombinant enzyme Extracellular DNA Pulmonary/Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Daily infusion of dornase alfa (Daily infusion of dornase alfa) — Fondation Ophtalmologique Adolphe de Rothschild. Dornase alfa is a recombinant human DNase that breaks down extracellular DNA in mucus to reduce viscosity and improve clearance.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Daily infusion of dornase alfa TARGET	Daily infusion of dornase alfa	Fondation Ophtalmologique Adolphe de Rothschild	phase 2	Recombinant enzyme	Extracellular DNA
Dornase alfa (Pulmozyme)	Dornase alfa (Pulmozyme)	University of Jena	marketed	Recombinant enzyme	Extracellular DNA (deoxyribonucleic acid)
rhDNAse	rhDNAse	The Hospital for Sick Children	marketed	Recombinant enzyme	Extracellular DNA (deoxyribonucleic acid)
Pulmozyme®	Pulmozyme®	AO GENERIUM	marketed	Recombinant enzyme	Extracellular DNA
Dornase Alfa Inhalant Solution [Pulmozyme]	Dornase Alfa Inhalant Solution [Pulmozyme]	University Hospital, Strasbourg, France	phase 3	Recombinant enzyme	Extracellular DNA (deoxyribonucleic acid)
Dornase Alfa Inhalation Solution	Dornase Alfa Inhalation Solution	University of Missouri-Columbia	phase 3	Recombinant enzyme	Extracellular DNA (deoxyribonucleic acid)
Fabrazyme (agalsidase beta)	Fabrazyme (agalsidase beta)	Genzyme, a Sanofi Company	marketed	Enzyme replacement therapy (ERT); recombinant enzyme	α-galactosidase A (GLA gene product); substrate: globotriaosylceramide (GL-3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant enzyme class)

The Hospital for Sick Children · 2 drugs in this class
AO GENERIUM · 1 drug in this class
Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
Protalix · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class
University of Jena · 1 drug in this class
AM-Pharma · 1 drug in this class
University of Missouri-Columbia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daily infusion of dornase alfa — Competitive Intelligence Brief. https://druglandscape.com/ci/daily-infusion-of-dornase-alfa. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab